ZVSA שווי כולל של נכסי החברה ZyVersa

ZyVersa Therapeutics employs a fabless approach, distributing molecule synthesis across certified US plants. The company's operating structure relies on external CRO contractors and a lean executive team with no staffing shortages. This chart reflects the current market value of total assets at 0.00, which complements the biotech's profile. Developments are based on an inflammasome platform to mitigate early-stage kidney inflammation and provide therapy for orphan diseases.

To identify a fundamental support level for the business of ZyVersa Therapeutics (ZVSA), which is developing unique inflammasome platforms for the therapy of nephropathies, an assessment of controlled resources is critical; through a reverse ROA calculation, this captures the aggregate of all tangible and intangible assets excluding market speculation, allowing the investor to determine the real value of the issuer's base and confirm the asset's reliability through compliance with strict listing criteria.